These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 17159195

  • 1. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 01; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
    Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA.
    J Clin Oncol; 2007 Mar 01; 25(7):829-36. PubMed ID: 17159193
    [Abstract] [Full Text] [Related]

  • 4. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 5. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 6. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May 01; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 7. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA.
    Clin Breast Cancer; 2009 May 01; 9(2):77-85. PubMed ID: 19433387
    [Abstract] [Full Text] [Related]

  • 8. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.
    Clin Breast Cancer; 2012 Feb 01; 12(1):40-8. PubMed ID: 22014381
    [Abstract] [Full Text] [Related]

  • 9. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 01; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 10. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P, Bundred N.
    Semin Oncol; 2007 Dec 01; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [Abstract] [Full Text] [Related]

  • 11. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C.
    N Engl J Med; 2009 Feb 12; 360(7):679-91. PubMed ID: 19213681
    [Abstract] [Full Text] [Related]

  • 12. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 13. Long-term implications of bone loss in breast cancer.
    Aapro MS.
    Breast; 2004 Dec 01; 13 Suppl 1():S29-37. PubMed ID: 15585380
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
    Lancet Oncol; 2011 Jul 01; 12(7):631-41. PubMed ID: 21641868
    [Abstract] [Full Text] [Related]

  • 15. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, Jung SY, Lee S, Kim SW, Kang HS.
    J Clin Oncol; 2010 Jun 01; 28(16):2705-11. PubMed ID: 20421538
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE.
    J Clin Oncol; 2004 Sep 15; 22(18):3694-9. PubMed ID: 15365065
    [Abstract] [Full Text] [Related]

  • 17. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.
    J Clin Oncol; 2010 Feb 20; 28(6):967-75. PubMed ID: 20065185
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar 20; 19(3):390. PubMed ID: 15828553
    [No Abstract] [Full Text] [Related]

  • 19. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R, Gesztesi Z, Rochford J.
    Can J Urol; 2010 Jun 20; 17(3):5170-7. PubMed ID: 20566009
    [Abstract] [Full Text] [Related]

  • 20. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T.
    J Obstet Gynaecol Res; 2007 Oct 20; 33(5):696-9. PubMed ID: 17845332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.